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http:WHAT THIS PAPER ADDS
Vascular cells shed membranous vesicles into the circulation associated with atherothrombotic processes that
have the potential to act as disease biomarkers. This pilot study demonstrates the potential of microparticles
shed from endothelial cells to predict plaque instability in patients undergoing carotid endarterectomy. The
study adds to a previous study demonstrating similar predictive ability of leucocyte microparticles. Ultimately,
microparticles may assist in the selection of carotid patients for surgical intervention.Objectives: Cell-derived microparticles (MPs) are small plasma membrane-derived vesicles shed from circulating
blood cells and may act as novel biomarkers of vascular disease. We investigated the potential of circulating MPs
to predict (a) carotid plaque instability and (b) the presence of advanced carotid disease.
Methods: This pilot study recruited carotid disease patients (aged 69.3  1.2 years [mean  SD], 69% male, 90%
symptomatic) undergoing endarterectomy (n ¼ 42) and age- and sex-matched controls (n ¼ 73). Plaques were
classiﬁed as stable (n ¼ 25) or unstable (n ¼ 16) post surgery using immunohistochemistry. Blood samples were
analysed for MP subsets and molecular biomarkers. Odds ratios (OR) are expressed per standard deviation
biomarker increase.
Results: Endothelial MP (EMP) subsets, but not any vascular, inﬂammatory, or proteolytic molecular biomarker,
were higher (p < .05) in the unstable than the stable plaque patients. The area under the receiver operator
characteristic curve for CD31þ41 EMP in discriminating an unstable plaque was 0.73 (0.56e0.90, p < .05).
CD31þ41 EMP predicted plaque instability (OR ¼ 2.19, 1.08e4.46, p < .05) and remained signiﬁcant in a
multivariable model that included transient ischaemic attack symptom status. Annexin Vþ MP, platelet MP (PMP)
subsets, and C-reactive proteinwere higher (p< .05) in cases than controls. Annexin VþMP (OR¼ 3.15, 1.49e6.68),
soluble vascular cell adhesion molecule-1 (OR¼ 1.64, 1.03e2.59), and previous smoking history (OR¼ 3.82, 1.38e
10.60) independently (p < .05) predicted the presence of carotid disease in a multivariable model.
Conclusions: EMP may have utility in predicting plaque instability in carotid patients and annexin Vþ MPs may
predict the presence of advanced carotid disease in aging populations, independent of established biomarkers.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The ability to identify carotid plaques that confer
increased risk would greatly assist in the selection of pa-
tients for carotid artery endarterectomy or stenting. Sim-
ple quantiﬁcation of carotid artery disease based on the
degree of stenosis has limitations and there is a need to
look beyond this parameter when assessing stroke risk.1
As atherosclerosis is a multifocal systemic disease that isof original article: http://dx.doi.org/10.1016/j.ejvs.2014.08.020
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//dx.doi.org/10.1016/j.ejvs.2014.08.007associated with diffuse lesions in the arterial tree, it is
likely that plaque characteristics at one vascular site are
reﬂective of plaque at other sites2 with plaque instability
potentially inﬂuenced by systemic processes.3 Molecules
associated with these atherothrombotic processes,
released into the circulation, have the potential to identify
the presence of atherosclerosis and the likelihood of an
unstable plaque that would beneﬁt from surgical inter-
vention. Several molecular biomarkers of carotid artery
disease, reviewed elsewhere,1 have been identiﬁed that
relate to the presence of disease, the degree of stenosis,
plaque vulnerability, symptom status, and stroke risk.
These include soluble cell adhesion molecules and selec-
tins, inﬂammatory markers, cytokines, and matrix metal-
loproteinases (MMPs).
Table 1. Descriptive characteristics (raw counts with percentages in parenthesis) of controls and cases, with cases subdivided by those with
stable and unstable plaques.
Controls
(n ¼ 73)
Cases
(n ¼ 42)
Stable
(n ¼ 25)
Unstable
(n ¼ 16)
Gender (%)
Male 40 (55%) 29 (69%) 18 (72%) 11 (69%)
Age (years) mean  SD 71.1  0.9 69.3  1.2 70.3  1.6 68.1  2.0
Smoking status (%)
Former 24 (33%) 23 (55%) 14 (56%) 9 (56%)
Current 9 (12%) 11 (26%) 5 (20%) 6 (38%)
Never 40 (55%) 8 (19%)* 6 (14%) 1 (6%)
Medications (%)
Anti-hypertensive 24 (33%) 37 (88%)* 22 (88%) 14 (88%)
Anti-platelet/anti-coagulant 14 (19%) 42 (100%)* 25 (100%) 16 (100%)
Lipid lowering 34 (45%) 39 (93%)* 23 (92%) 15 (94%)
Glucose control 3 (4%) 5 (12%) 5 (20%) 0
Cases
Main diagnosis (%)
Asymptomatic 4 (16%) 0
Amaurosis fugax 5 (20%) 1 (6%)
Transient ischaemic attack 16 (64%) 15 (94%)y
High creatinine (>90 mmol/L) 10 (40%) 6 (38%)
*p < .05 compared to control group.yp < .05 compared to stable plaque group. Comparisons evaluated using the chi-square test.
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biomarkers of atherosclerotic disease. MPs are vesicles,
0.1e1.0 mm diameter, that are shed from the plasma
membrane of vascular cells including platelets, endothelial
cells, erythrocytes, and leucocytes. Triggers for vesicle
budding and release include cell activation and apoptosis.
Increased levels of endothelial microparticles (EMPs),4
platelet microparticles (PMPs),5 and leucocyte microparti-
cles (LMPs)6 have been reported in the plasma of patients
with atherosclerotic diseases compared with matched
controls. In addition, there is some evidence that MP can
discriminate vascular disease severity and damage.4,7e9
Only two studies to date have investigated MP in relation
to carotid artery disease plaques. Using an indirect assess-
ment of PMP, Michelsen and colleagues10 reported no dif-
ference in PMPs between those with echogenic (highly
ﬁbrous calciﬁed plaques) and echolucent plaques (plaques
with high lipid content). In contrast, Sarlon-Bartoli and
colleagues11 demonstrated potential for a LMP subset in
discriminating an unstable plaque.
The purpose of this study was to determine the ability of
EMP and PMP to predict carotid plaque instability in pa-
tients undergoing endarterectomy and the presence of
advanced carotid disease in a cohort of cases and matched
controls. In addition to MP, a range of more frequently
measured molecular biomarkers were measured to deter-
mine the additional value that might result from including
MP in multivariable prediction models.METHODS
Study overview
This prospective caseecontrol study recruited men and
women with (cases) and without (controls) documented
carotid artery disease. The study set out to include allpatients undergoing carotid endarterectomy at the regional
vascular surgery unit over a 2-year period. Of these 46
patients, three could not be recruited for logistical reasons,
and 42 of the remaining 43 patients consented to taking
part. Post surgery, the excised plaques were graded as
stable or unstable using immunohistochemistry based on
the protocol of Redgrave et al.12 that assesses inﬂammatory
cell inﬁltration in the plaque and cap, evidence of plaque
rupture, and surface thrombus. One plaque was incorrectly
processed and lost to analysis. When carotid endarterec-
tomy was performed on both the right and left sides
(n ¼ 6), only the ﬁrst surgery data were included in the
biomarker analyses, as surgical injury could potentially in-
ﬂuence MP counts. Both plaques were graded however. The
controls (n ¼ 73) were matched for age and sex and
recruited from a local general practice and the locality.Study population and ethics
The descriptive characteristics of the participants are sum-
marized in Table 1. Clinical and paraclinical data for the
cases was obtained from medical charts. Of the 41 cases, 37
were symptomatic with transient ischemic attack (TIA), the
most common presenting symptom. The median lag time
between the development of symptoms and surgery was 21
(interquartile range 11e58) days. The only exclusion crite-
rion for carotid patients was an inability to consent because
of greatly diminished cognitive function. The exclusion
criteria for controls included a history of coronary artery
disease, cerebrovascular disease, peripheral arterial disease,
aneurysmal disease, or cancer. Suitable controls were
identiﬁed by a general practitioner from a local practice,
and the absence of exclusion criteria was also veriﬁed by
self-report. Information on prescribed medication classes
and smoking history was obtained from controls using a
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of study investigators. Written informed consent was ob-
tained from all participants, and the study was approved by
an institutional and a hospital ethics committees.Blood collection and processing
All blood samples were taken in the morning following an
overnight fast, with cases sampled on the morning of sur-
gery. The ﬁrst 3.0 mL was discarded. Samples were kept at
room temperature prior to centrifugation and processed
within 2 hours of collection. Cases and controls continued
to take prescribed medications in the days leading up to
blood sampling. However, with the exception of aspirin,
anti-platelet, and anti-coagulant medications ceased to be
taken by cases 1 week prior to surgery.
The serum tubes were centrifuged for 15 minutes at
1500g at 20 C. The upper part of the serum and plasma
was collected down to 1 cm above the buffy coat layer. The
sodium citrate tubes (3.2%), for MP analysis, underwent a
double centrifugation protocol. They were ﬁrst centrifuged
for 15 minutes at 1500g at 20 C, followed by 2 minutes at
13,000g at 20 C to produce platelet poor plasma, with the
pellet discarded. Aliquots ofw350 mL of serum and plasma
were stored at 80 C for later analysis.Vascular imaging of arteries
The carotid arteries were examined for the presence of
plaque in the common, internal and external vessels and at
the bifurcation area bilaterally. Vertebral arteries were
checked for patency. Blood ﬂow velocity was measured at a
standard 60 interrogation angle. The percentage degree of
narrowing (stenosis) in the blood vessel was calculated
based on the Strandness criteria. Control scans were re-
ported as abnormal when the percentage vessel stenosis
was >70%. One control volunteer with >70% stenosis was
excluded from the study.Immunohistochemical analysis of plaques
Plaques were collected immediately after excision, and
preserved in 10% buffered formalin until processed. Pro-
cessing of the plaques was undertaken not more than 24
hours after collection. All plaques were ﬁxed in 10%
formalin for 24 hours and decalciﬁed using formic acid for a
further 24 hours. The area of maximum disease was iden-
tiﬁed macroscopically, typically the thickest part of plaque,
or where the lumen was most narrowed, or any obvious
thrombus. Representative transverse sections were taken
from these areas (3e4 mm thick each) and then embedded
in parafﬁn wax in an automated embedder (Tissue-Tek
AutoTEC Sakura). These blocks were sectioned at w3 mm
and immunostained on the Leica BOND-MAXTM automated
immunostainer using the Bond Polymer Reﬁne Detection
kit. The sections were analysed for the presence of
macrophage and T-cells using CD68 (Dako Denmark, clone
PG-M1, dilution 1:50) and CD3 (Leica Clone LN-10, pre-
diluted) antibodies respectively.Grading of the plaques
Plaques were graded based on a previously published
method, using semi-quantitative scales.12 For this study,
four immunohistological features were associated with un-
stable plaques. These were the presence of inﬂammatory
cells (macrophage or lymphocytes stained respectively with
CD68 or CD3 antibody) in the plaque core or plaque cap
area, cap rupture (a break or erosion of the ﬁbrous cap
overlying the lipid core) or surface thrombus (identiﬁed
adherent to the luminal surface of the plaque). The in-
ﬂammatory cell proliferation in the plaque core and in the
cap was graded separately on a scale of 1e3 for both CD68
and CD3 content. Grades 1, 2, and 3 represented occasional
cells, one group of >50 cells, and two to ﬁve groups of
>50 cells respectively. This gave a total inﬂammatory cell
score of between 4 and 12, with 12 representing high CD68
and CD3 content in both the plaque core and the cap area.
Plaques were regarded as unstable if they had any of the
following: inﬂammatory cell score of between 9 and 12,
evidence of cap rupture, or evidence of surface thrombus.
The histopathologist classifying the plaques was blinded to
the presenting symptom (if any) of the case and to all
biomarker concentrations.
Microparticle and molecular biomarker enumeration
MPs were deﬁned based on size (<1.0 mm) and ﬂuorescence
using ﬂow cytometry. Annexin V binds to negatively charged
phospholipids and annexin Vþ events within this size gate
represent MP shed from various vascular cell types under-
going apoptosis. Annexin VþMP and two different subsets of
PMP were enumerated, CD41þ PMP and AnnexinVþCD41þ
PMP, from thawed unwashed plasma. Plasma samples were
washed twice in PBS-citrate prior to EMP enumeration. Two
different EMP subsets were enumerated, MP expressing
CD31 but not expressing the platelet marker CD41
(CD31þCD41 EMP) and MP expressing one or more of the
endothelial speciﬁc markers CD144, CD146, CD105 in a
monochrome multimarker assay (mmEMP). This mono-
chromemultimarker approach was previously employed13 to
improve the signal to noise ratio, given the low number of
these endothelial speciﬁc markers on particles of small sur-
face area. Soluble vascular injury, and angiogenic and pro-
teolytic biomarkers were analysed in duplicate using
commercially available immunoassays (Meso Scale Discov-
ery, Rockville, MD, USA) employing multiplexing technology
and electrochemiluminescence detection.
Statistics
As the majority of biomarkers were not normally distributed
(KolmogoroveSmirnov test), non-parametric statistics were
employed. Data are presented as median (inter-quartile
range). Between group differences were compared using the
ManneWhitney U test and the chi-square test for categorical
variables. The discriminative ability of putative biomarkers
was quantiﬁedwith reference to the concordance statistic (C-
statistic) of each receiver operator characteristic curve (ROC),
which represents the area under the curve (AUC). Multiple
Table 2. Microparticle and molecular biomarkers in carotid artery disease cases and matched controls with cases subdivided into those
with stable and unstable plaques.
Biomarker Controls
(n ¼ 73)
Stable plaque
(n ¼ 25)
Unstable plaque
(n ¼ 16)
Combined cases
(n ¼ 42)
Microparticles
Annexin Vþ MP (events/mL) 632 (377e812) 799 (477e1426) 1013 (381e1643) 805 (428e1427)*
CD41þ PMP (events/mL) 358 (233e571) 600 (340e745) 535 (355e1369) 595 (34 2e933)*
AnnexinVþCD41þ PMP (events/mL) 248 (164e450) 406 (220e686) 438 (132e1139) 413 (200e792)*
mmEMP* (events/mL) 1.13 (0.55e2.09) 0.73 (0.40e1.61) 1.88 (1.05e2.97)y 1.05 (0.53e2.08)
CD31þ41 EMP (events/mL) 0.75 (0.54e1.31) 0.62 (0.33e1.02) 1.30 (0.60e1.77)y 0.72 (0.41e1.33)
Molecular biomarkers
C-reactive protein (mg/L) 1.49 (0.68e6.08) 3.3 (0.9e11.2) 4.2 (1.1e11.3) 3.06 (1.01e11.06)*
Serum amyloid A (ng/mL) 1617 (765e3748) 2166 (1091e5318) 1942 (1193e16182) 2102 (1167e5207)a
sVCAM-1 (ng/mL) 368 (270e472) 437 (353e567) 396 (285e529) 411 (338e550)b
sICAM-1 (ng/mL) 107 (84e152) 140 (104e166) 128 (99e158) 132 (101e162)
sE-selectin (ng/mL) 14.9 (10.4e18.0) 13.3 (10.6e15.1) 12.7 (6.1e17.1) 13.0 (9.6e16.5)
VEGF (pg/mL) 519 (288e869) 338 (234e926)
VEGF-C (pg/mL) 453 (396e520) 410 (282e638)
VEGF-D (pg/mL) 859 (699e1060) 882 (686e1224)
PIFG (pg/mL) 23.8 (21.0e28.0) 19.2 (18.6e26.4)
Tie-2 (pg/mL) 4598 (3765e5527) 5014 (4100e6132)
sFlt-1 (pg/mL) 109 (85e134) 123 (98e175)
bFGF (pg/mL) 6.4 (3.3e8.7) 3.8 (2.1e5.2)
MMP-1 (pg/mL) 20213 (9802e24484) 20097 (9333e26587)
MMP-2 (pg/mL) 83894 (73926e95042) 72666 (62181e90010)
MMP-3 (pg/mL) 11926 (9393e16039) 13365 (9676e16756)
MMP-9 (ng/mL) 210 (158e386) 197 (172e370)
MMP-10 (pg/mL) 1349 (977e1915) 1738 (1330e2372)
Note. Values are median (inter-quartile range). MP ¼ microparticles; PMP ¼ platelet microparticles; EMP ¼ endothelial microparticles;
mmEMP, monochrome multimarker EMP, MP positive for one or more of the endothelial markers CD144, CD146, or CD105;
ICAM ¼ intercellular adhesion molecule; MMP ¼ matrix metalloproteinase; sFlt-1 ¼ soluble fms-like tyrosine kinase-1;
VEGF ¼ vascular endothelial growth factor; sVCAM-1 ¼ soluble vascular cell adhesion molecule-1, bFGF ¼ basic ﬁbroblast growth
factor, PlGF ¼ placental growth factor. *p < .05 cases vs. controls; ap ¼ 0.067 cases vs. controls; bp ¼ 0.087 cases vs. controls;
yp < .05 stable vs. unstable.
492 A.L. Wekesa et al.logistic regression analysis with forward stepwise entry of
variables (likelihood ratio) was used to identify the inde-
pendent predictors of unstable plaques and carotid artery
disease. Into the model to predict unstable plaques were
entered eligible (p < .10) biomarkers and categorical vari-
ables (CD31þ41 EMP and TIA symptom status) following
single logistic regression analyses. Into the model to predict
carotid artery disease cases were entered eligible (p < .10)
biomarkers (annexin Vþ MP, CD41þ PMP, annexin VþCD41þ
PMP, mm EMP, CRP, SAA and sVCAM-1 and smoking history)
from single logistic regression analyses. This multivariable
analysis was undertakenwith andwithout the entry of aspirin
(other anti-platelet agents had been withdrawn), anti-
lipaemic medications, and anti-hypertensive medications as
confounding variables. Odds ratios (ORs) and 95% conﬁdence
intervals (CIs) for these logistic regression analyses are
expressed per standard deviation biomarker increase. The
study was designed to detect a 25% difference in annexin Vþ
MP counts with 40 cases and 60 controls, assuming a statis-
tical power of 0.80 and p< .05, based on previous laboratory
data. Signiﬁcance was set as p < .05.
RESULTS
Of the 41 carotid endarterectomy cases, 37 (90%) were
symptomatic and four (10%) asymptomatic, 25 (61%) withstable and 16 (39%) with unstable plaques (Table 1). All of
the asymptomatic cases had stable plaques. In ﬁve of the six
cases where carotid artery endarterectomy was required on
the left and right sides, the carotid plaques had the same
stable/unstable classiﬁcation. The percentage of cases with
a primary diagnosis of TIA was higher (p ¼ .03) in the un-
stable plaque group (Table 1).
CD31þCD41 EMP and mmEMP were 2.1- and 2.6-fold
higher (p < .05) respectively in patients with unstable
compared with stable plaques (Table 2). Annexin Vþ MP,
CD41þ PMP, and annexin VþCD41þ PMP were not different
in the unstable compared to the stable plaque group
(Table 2). None of the vascular, inﬂammatory, angiogenic, or
proteolytic markers measured were different between
these groups (Table 2). CD31þ41 EMPs were also higher in
patients with TIA symptoms than in those who were
asymptomatic (Fig. 1). No MP subset was different in pa-
tients that underwent endarterectomy within 21 days
(median lag time) of developing symptoms compared to
those with later surgeries. The C statistics for the ROC
curves based on CD31þ41 EMP and mmEMP were 0.73 (CI
0.56e0.90, p ¼ 0.016) and 0.73 (CI 0.58e0.89, p ¼ 0.012)
respectively (Fig. 2). Using single logistic regression analysis,
only CD31þ41 EMP (OR ¼ 2.34, CI 1.18e4.66, p ¼ .015)
signiﬁcantly predicted an unstable plaque, though TIA
Figure 1. CD31þ41 endothelial microparticles in carotid artery
disease patients who presented with no symptoms, amaurosis
fugax, and transient ischemic attack. Note. Values are median
(interquartile range). Asymp. ¼ no symptoms; AF ¼ amaurosis
fugax; TIA ¼ transient ischaemic attack. *p < .05 compared to
asymptomatics.
Table 3. Predicting carotid artery disease from microparticle and
molecular biomarkers.
Biomarker ROC AUC (95% CI) p
Microparticles
Annexin Vþ MP 0.68 (0.57e0.79) 0.002
CD41þ PMP 0.68 (0.57e0.79) 0.002
AnnexinVþCD41þ PMP 0.66 (0.55e0.77) 0.01
mm EMP 0.53 (0.41e0.65) 0.60
CD31þ41 EMP 0.52 (0.41e0.64) 0.70
Molecular biomarkers
C-reactive protein 0.63 (0.52e0.74) 0.02
sVCAM-1 0.61 (0.50e0.72) 0.06
Serum amyloid A 0.60 (0.49e0.71) 0.08
sICAM-1 0.59 (0.47e0.70) 0.14
sEselectin 0.41 (0.30e0.53) 0.14
ROC AUC ¼ receiver operator characteristic curve area under
curve; CI ¼ conﬁdence interval; MP ¼ microparticles;
PMP ¼ platelet microparticles; EMP ¼ endothelial
microparticles; mmEMP ¼ monochrome multimarker EMP, MP
positive for one or more of the endothelial markers CD144,
CD146, or CD105.
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the criterion for inclusion in the multivariable model. Using
multiple logistic regression analysis, CD31þ41 EMP
remained a signiﬁcant predictor of an unstable plaque
(OR ¼ 2.19, CI 1.08e4.46, per SD increase, p ¼ .03) even
with TIA symptom status in the model.
Annexin Vþ MP, CD41þ PMP, annexin VþCD41þ PMP, and
C-reactive protein (CRP) were higher (p < 0.05) in cases
than controls (Table 2). CD31þCD41 EMP, mmEMP, soluble
E-selectin (sE-selectin), soluble intercellular adhesion
molecule (sICAM-1), soluble vascular cell adhesion molecule
(sVCAM-1), and serum amyloid A (SAA) (p ¼ 0.067) were
not different in cases and controls (Table 2). The prevalence
of previous smoking history and of anti-lipaemic, anti-Figure 2. Receiver operator characteristic curve to discriminate an
unstable carotid plaque based on CD31þ41 EMP and mmEMP.
Note. EMP ¼ endothelial microparticles; mmEMP ¼ monochrome
multimarker EMP, MPs positive for one or more of the endothelial
markers CD144, CD146, or CD105.hypertensive, and anti-platelet therapy was higher (p < .05)
in the cases than controls (Table 1). The ability of MPs and
molecular biomarker variables to discriminate carotid artery
disease cases from controls is shown in Table 3. The C
statistic for the ROC curve was signiﬁcant (p < .05) for
annexin Vþ MP, CD41þ PMP, and CRP and marginally higher
for the MPs (0.66e0.68) than the molecular (0.61e0.63)
markers. Annexin Vþ MP (OR ¼ 3.15, 1.49e6.68, p ¼ .003),
sVCAM-1 (OR ¼ 1.64, 1.03e2.59, p ¼ .03), and previous
smoking history (OR ¼ 3.82, 1.38e10.60, p ¼ .01) were
signiﬁcant in a multiple logistic regression model to predict
carotid artery disease. When aspirin, anti-lipaemic medica-
tions, and anti-hypertensive medications were entered into
the model, annexin Vþ MPs (OR ¼ 10.56, 2.07e53.75,
p ¼ .005) and CRP (OR ¼ 2.44, 1.17e5.11, p ¼ .018)
emerged as the independent biomarker predictors.DISCUSSION
This was a pilot study to examine the predictive potential of
MPs, novel biomarkers, in carotid artery disease. When
patients with stable and unstable carotid plaques were
compared, the CD31þ41 EMP and the mmEMP subsets
were higher in the unstable plaque group. The area under
the ROC curve was similar for both EMP subsets. CD31þ41
EMPs were also signiﬁcantly higher in patients presenting
with TIA than those who were asymptomatic, albeit with a
very small sample size of asymptomatics. CD31þ41 EMPs
emerged as the single signiﬁcant biomarker of an unstable
plaque in a multivariable analysis, and remained signiﬁcant
even after adjusting for TIA symptom status. In contrast,
none of the vascular inﬂammatory, proteolytic, or angio-
genic factors measured were different between these
groups. When biomarker concentrations in carotid artery
disease cases and matched controls were compared,
annexin Vþ MPs, CD41þ MPs, annexin VþCD41þ MPs, and
the inﬂammatory marker CRP were all higher in the cases.
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advanced carotid artery disease, but not the speciﬁc PMP
subsets. This is not surprising as the majority of annexin Vþ
events are derived from platelets.14
Different EMP and PMP subsets were enumerated in this
study, an approach not uncommon in the MP literature. A
limitation of MP research is the wide range of deﬁnition
markers and marker combinations that are used in clinical
studies to identify MPs, particularly EMPs. Indeed, there is
evidence that speciﬁc EMP subsets can reﬂect different
pathophysiological processes.15 Both EMP subsets but not
PMPs were higher in those with unstable than stable pla-
ques whereas both PMP subsets and annexin Vþ MPs
(mainly PMPs) but not EMPs were higher in cases than
controls. CD31þ41 EMPs emerged in this study as the
predictor of an unstable plaque, and annexin Vþ MP as the
most consistent predictor of advanced carotid disease
present in two different models. Ideally, the same MP
subset would predict an unstable plaque and the presence
of advanced carotid disease. However, biomarkers need not
have universal utility and different cardiovascular bio-
markers may be needed to screen for a disease, identify
unstable patients and monitor treatment.16
Mechanistic studies clearly indicate that MPs are more
than cellular debris shed from diseased vascular tissue.
EMPs harbour functional molecules that are involved in
inﬂammation, coagulation, endothelial cell function, and
angiogenesis.17 EMPs generated in vitro expose MMP-2 and
MMP-9, potentially contributing to plaque destabilization.18
EMPs also promote premature endothelial cell senes-
cence.19 Thus, in addition to their biomarker role, MPs may
be mediators of disease progression in the carotid artery
and also at other sites throughout the vascular tree.
The study employed an extensive panel of molecular
markers for comparison purposes with the MP markers. As
the immunoassay techniques to quantify these molecular
biomarkers are better established and more widely avail-
able than the ﬂow cytometry techniques used to enumerate
MPs, MPs need to clearly add to risk prediction. CRP and
sVCAM-1 featured in different multivariable models to
predict carotid disease cases, but the combination of mo-
lecular markers did not displace annexin Vþ MP from either
model. None of the proteolytic, vascular inﬂammatory, or
angiogenic markers analysed predicted plaque instability.
Contrary to previous studies,20,21 the MMP enzymes ana-
lysed were not different between plaque groups, even
though a full MMP panel was assessed. Of note, no cyto-
kines were quantiﬁed. We cannot therefore be certain that
MPs would emerge as independent predictors had our
models included cytokines and chemokines that have
demonstrated potential in identifying unstable plaques such
as CCL522 and TNF-a.23
A clear limitation of the study, indeed of many casee
control biomarker studies, is the potential confounding ef-
fect of prescribed medications on biomarker concentrations.
Anti-lipaemic, anti-platelet, and anti-hypertensive medica-
tion usage was considerably greater in the group of cases.
Studies generally show a reduction in MPs after treatmentwith statins,24 clopidogrel,25 and cilostazol26 but not
aspirin.27 This potential confounding effect was examined by
undertaking the multiple logistic regression analysis with
and without prescribed medications as confounding factors.
Annexin Vþ MP was signiﬁcant in both models though the
odds ratio was considerably greater when prescribed med-
ications were entered. Soluble VCAM-1 was signiﬁcant in the
ﬁrst model but displaced by CRP when prescribed medica-
tions were entered. Prediction models that do not include
biomarker-lowering medications as covariates potentially
underestimate biomarker predictive values. There are di-
lemmas however in adjusting for multiple confounders in
small datasets, especially as nearly all cases were using
aspirin, anti-lipid, and anti-hypertensive agents. Adjusted
ORs can be inﬂated in these circumstances, and the prob-
lems caused by further adjustment can begin to outweigh
the confounding controlled.28 In addition, biomarkers need
to be able to predict increased risk of disease or disease
stage even in heavily medicated populations for them to
have clinical utility. A conservative approach is sometimes
warranted by excluding medications from analyses.
The small sample size, particularly for the stableeunstable
comparison, is another limiting factor in this study. Although
clear potential has been demonstrated for CD31þ41 EMP
and annexin VþMP, there is not sufﬁcient statistical power to
demonstrate their superiority over other subsets that were
also signiﬁcantly different in the stableeunstable and casee
control comparisons. In addition, we did not regard it as
appropriate to identify speciﬁc risk cut-offs in a small sample
and to determine the discriminative value associated with
these cut-offs from this same cohort. To our knowledge, only
one other study,11 employing a similar sample size, demon-
strated the potential of one LMP subset to distinguish stable
from unstable carotid plaques graded post endarterectomy.
These studies should be regarded as complementary,
together demonstrating the potential of speciﬁc EMP and
LMP subsets but not PMP to predict plaque instability.
Further, possibly multicentre research studies, with consid-
erably larger samples sizes are justiﬁed. The majority of the
cases in this study were symptomatic.Thus we do not know if
EMPswere released after the development of symptoms or if
they are also elevated in asymptomatic individuals with
vulnerable plaques. Other research approaches are needed.
Two prospective studies have demonstrated prognostic po-
tential of EMPs and for total cardiovascular events in high-risk
cohorts.29,30 A key requirement of future carotid studies will
be to examine the prognostic potential of both EMP and LMP
in identifying asymptomatic individuals who will develop
symptoms or suffer a major cerebrovascular event.
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